NCT00575224View on ClinicalTrials.gov

Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Chronic Hepatitis CAsian AmericansNovel GenotypesTreatment
Interventions
DRUG

Pegylated interferon and ribavirin

180 ug of peg-IFN per week and 1000-1200 mg of ribavirin per day (weight-dependent). Treatment duration is determined by treatment arm.

Trial Locations (5)

75093

Digestive Health Associates of Texas, Plano

77072

Houston Gastroenterology Clinic, Houston

92115

San Diego Gastroenterology Clinic, San Diego

92843

Westminster Gastroenterology Clinic, Westminster

95116

San Jose Gastroenterology, San Jose

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

Pacific Health Foundation

OTHER

NCT00575224 - Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9 | Biotech Hunter | Biotech Hunter